What is IMRIS?
IMRIS Inc. specializes in the design, manufacturing, and worldwide distribution of image-guided therapy solutions. Its flagship product, the VISIUS Surgical Theatre, integrates advanced imaging modalities such as MRI, CT, and fluoroscopy directly into multi-purpose operating rooms. This technology empowers clinicians with real-time intraoperative vision, crucial for enhancing precision and decision-making in complex neurosurgical, spinal, cerebrovascular, and cardiovascular procedures. The company serves hospitals by bringing cutting-edge imaging capabilities directly to the point of care, complemented by service contracts and accessory sales. Founded in 2005, IMRIS operates within the critical intersection of medical technology and surgical intervention.
How much funding has IMRIS raised?
IMRIS has raised a total of $67.4M across 2 funding rounds:
Stock Offering
$42.4M
Other Financing Round
$25M
Stock Issuance/Offering (2007): $42.4M, investors not publicly disclosed
Other Financing Round (2013): $25M led by Deerfield
Key Investors in IMRIS
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
What's next for IMRIS?
The recent major strategic investment positions IMRIS for significant advancements in its market segment. With a substantial total funding history, the company is poised to further refine its VISIUS Surgical Theatre technology and expand its global reach. This capital infusion is expected to fuel research and development, enhance manufacturing capabilities, and bolster sales and marketing efforts. The focus on enterprise-level funding suggests a strategic push towards larger hospital systems and integrated healthcare networks, aiming to solidify its role as a leader in intraoperative imaging and image-guided therapy.
See full IMRIS company page
